Inactivation of the TP53 tumor suppressor gene is essential during cancer development and progression. Mutations of TP53 are often missense and occur in various human cancers. In some fraction of wild-type (wt) TP53 tumors, p53 is inactivated by upregulated murine double minute homolog 2 (MDM2) and MDM4. We previously reported that simultaneous knockdown of MDM4 and MDM2 using synthetic DNAmodified siRNAs revived p53 activity and synergistically inhibited in vitro cell growth in cancer cells with wt TP53 and high MDM4 expression (wtTP53/highMDM4). In the present study, MDM4/MDM2 double knockdown with the siRNAs enhanced 
K E Y W O R D S
5-fluorouracil, colon cancer, gastric cancer, MDM4, p53 double minute 2 (MDM2) and MDM4. [6] [7] [8] MDM2 and its complex with MDM4 destabilizes p53 through binding and ubiquitin-dependent protein degradation. 9, 10 MDM4 can also repress p53 transcriptional activity by directly binding to the transactivating domain. 11, 12 Studies have shown that reactivation of wild-type (wt) TP53
by inhibiting MDM2-p53 interaction or knockdown of MDM2 and MDM4 induces cell cycle arrest and apoptotic cell death, inhibiting tumor growth in tumors carrying wtTP53. 6, [13] [14] [15] [16] [17] [18] [19] Thus, MDM2 and MDM4 are ideal targets for cancer therapy in such tumors. Various kinds of small molecular compounds and peptides inhibiting MDM2 function have been developed. 6, 18, 20, 21 Among them, idasanutlin has been shown to be an effective treatment in some clinical studies of patients with malignant lymphomas and acute myeloblastic leukemias.
22-24
A previous study reported that cultured tumor cells with wtTP53
can be divided into 2 types: high MDM2 expressers and high MDM4 expressers. 16 reactivation of wtTP53 by chiMDM4 and chiMDM2 could be used for the treatment of these cancers. In the present study, the effects of double knockdown of MDM4 and MDM2 using chiMDM4 and chiMDM2 on the antitumor activity of 5-FU in colon and gastric cancer cells with wtTP53 and high MDM4 (wtTP53/highMDM4) were investigated. In vivo antitumor activity of chiMDM4 plus chiMDM2 (chiMDM4/chiMDM2) and a combination of chiMDM4/chiMDM2
with 5-FU were also explored.
| MATERIAL S AND ME THODS

| Cell culture
Four tumor cell lines with wtTP53 were used: HCT116 colon cancer,
LoVo colon cancer, SNU-1 gastric cancer, and NUGC-4 gastric cancer. The HCT116 cell line was purchased from Horizon Discovery Ham's F-12 nutrient mixture medium (Sigma-Aldrich) with 10% FBS.
5-Fluorouracil was purchased from Kyowa Hakko Kirin (Tokyo, Japan).
Nutlin-3 was purchased from Calbiochem (San Diego, CA, USA).
| Small interfering RNAs and transfection
Sequences of DNA-modified siRNAs used in this study were: 
| Cell viability
Water-soluble tetrazolium salt (WST-8) colorimetric assays were carried out using a CCK-8 (Dojin Laboratories, Kumamoto, Japan) according to the manufacturer's protocol. Because the maximum knockdown effects of siRNAs were usually observed 2-3 days after transfection, cells were incubated for 5 days after transfection with siRNAs (4 days after treatment with 5-FU), which was longer than the period described in the manufacturer's protocol (1-3 days), then analyzed using an iMark microplate reader (Bio-Rad, Hercules, CA, USA). The absorbance of the plates was read at wavelengths of 450 and 620 nm.
| Combination index
Quantification of the mixture of chiMDM4/chiMDM2 and 5-FU synergy was determined by the Chou-Talalay method for drug combination using CalcuSyn software (Biosoft, Cambridge, UK). 
| Immunoblot analysis
Both SDS-PAGE and immunoblot analysis were carried out as previously described. 16 The primary and secondary Abs used in this study were:
mouse mAb against MDM2 (2A10) (Abcam, Cambridge, UK); goat poly- 
| In vivo antitumor effect of 5-FU plus knockdown of MDM4 and MDM2
All animal experiments were undertaken according to procedures approved by the Institutional Animal Care and Use
Committee of the University of Tsukuba (Tsukuba, Japan).
Female BALB/c nude mice (5 weeks old) were obtained from
Charles River Japan (Kanagawa, Japan) and maintained under 
| Statistical analysis
Statistical significance of differences between various groups was evaluated using Dunnett's or Tukey's test (in vitro assay). A repeatedmeasures ANOVA was used to evaluate the in vivo antitumor effects of the drugs. A difference between the experimental groups was considered statistically significant at a P-value of <.05. All statistical analyses were undertaken using SPSS version 25.0 (SPSS, Chicago, IL, USA).
| RE SULTS
| Cell growth inhibition of MDM4/MDM2 double knockdown and 5-FU in wt TP53 colon and gastric cancer cells
To test if double knockdown of MDM4 and MDM2 could enhance the antitumor activity of 5-FU in colon and gastric cancers with wtTP53/ highMDM4, the effect of chiMDM4/chiMDM2 on the growth inhibitory activity of 5-FU was examined by WST-8 assay using 2 colon cancer (HCT116 and LoVo) and 2 gastric cancer (SNU-1 and NUGC-4) cell lines. As shown in Figure 1A 
HCT116
We tested whether nutlin-3, an inhibitor of MDM2-p53 interaction, could serve as a substitute for chiMDM2 to enhance the antitumor effect of chiMDM4 in 4 cell lines (NUGC-4, SNU-1, HCT116, and LoVo). As shown in Figure 2A and Table 2 , a synergistic antitumor effect of chiMDM4 and nutlin-3 was observed in 3 cell lines (NUGC-4, HCT116, and LoVo), whereas a mostly additive effect was seen in the SNU-1 cell line. Next, we examined whether the combination of chiMDM4/nutlin-3 could enhance the antitumor effect of Figure 2B , Table 3 ). We found that chiMDM4/nutlin3 synergistically enhanced the 5-FU effect in HCT116 (CI, 0.55-0.93), whereas its effect was additive or even antagonistic to 5-FU in NUGC-4 (CI, 0.82-1.42).
5-FU in HCT116 and NUGC-4 cells (
| Expression of MDM2, MDM4, p53, and their downstream molecules by MDM4/ MDM2 double knockdown
To explore the mechanisms by which chiMDM4/chiMDM2 en- Table S1 . than either alone in all tested cell lines. As a result, induction of p53
and p21 was highest in these cells treated with chiMDM4/chiMDM2 plus 5-FU compared with cells treated with either alone.
Although both MDM2 and p21 were products of p53-responsive genes, 5-FU increased the p21 level less than the MDM2 level in 
| In vivo antitumor activity
To test whether chiMDM4/chiMDM2 could inhibit in vivo tumor 
| D ISCUSS I ON
5-FU is widely used for chemotherapy in various cancers including colon, stomach, and breast cancer. In our previous study, simultaneous knockdown of MDM4 and MDM2 using synthetic DNA-substituted siRNAs (chiMDM4 and chiMDM2) was shown to synergistically suppress the growth of cancer cells with wtTP53/ highMDM4. 16 In this study, we showed that double knockdown of knockdown using chiMDM4/chiMDM2 might disrupt these negative effects of MDM2 on p53-and p21-mediated growth inhibition and potentiate the antitumor activity of 5-FU.
We revealed that chiMDM4-mediated growth inhibition could be synergistically enhanced by nutlin-3, as was observed by chiMDM2. 34 However, enhancement of 5-FU antitumor activity by chiMDM4/nutlin-3 was less efficient than that by chiMDM4/ which could be one of the mechanisms by which some cancer cells acquire resistance to p53-triggered apoptosis.
In the present study, we show that MDM4/MDM2 double knockdown inhibits in vivo tumor growth and enhances the antitumor effect of 5-FU without any intolerable toxicity. Recent advances in the delivery system for oligonucleotides 47 could enable chiMDM4/chiMDM2 to be applied to the treatment of wtTP53/ highMDM4 tumors. Approximately 50% of human cancers express wtTP53, 48 in some fraction of which wtTP53 is directly suppressed by MDM2 alone or MDM2 combined with MDM4. Thus, MDM2 and MDM4 are ideal targets of therapy for these tumors.
In addition, MDM2 knockout was shown to suppress the growth of tumors lacking TP53 alleles by inducing p53-responsive gene through TP73-mediated transactivation. 49 MDM4/MDM2 knockdown can be potentially used for the treatment of cancers lacking p53 expression.
In conclusion, the double knockdown of MDM4 and MDM2 enhances in vitro and in vivo antitumor activity of 5-FU toward gastrointestinal cancer with wtTP53/highMDM4. Combination of siRNAs targeting MDM4 and MDM2 and cytotoxic anticancer drugs including 5-FU could be a novel therapeutic strategy for such cancers.
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